Related references
Note: Only part of the references are listed.Early relapsed disease of multiple myeloma following up-front HDM-ASCT: a study based on the Danish Multiple Myeloma Registry in the period 2005 to 2014
Sissel Helm-Petersen et al.
LEUKEMIA (2018)
Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial
Brian G. M. Durie et al.
LANCET (2017)
Benefit of continuous treatment for responders with newly diagnosed multiple myeloma in the randomized FIRST trial
N. J. Bahlis et al.
LEUKEMIA (2017)
Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma
Michel Attal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
The impact of comorbidity on mortality in multiple myeloma: a Danish nationwide population-based study
Henrik Gregersen et al.
CANCER MEDICINE (2017)
Melphalan, prednisone, and lenalidomide versus melphalan, prednisone, and thalidomide in untreated multiple myeloma
Sonja Zweegman et al.
BLOOD (2016)
VTD is superior to VCD prior to intensive therapy in multiple myeloma: results of the prospective IFM2013-04 trial
Philippe Moreau et al.
BLOOD (2016)
The Danish National Multiple Myeloma Registry
Peter Gimsing et al.
CLINICAL EPIDEMIOLOGY (2016)
Continued improvement in overall survival in elderly multiple myeloma patients after 2008; a population based study from the Danish Multiple Myeloma Registry
N. Abildgaard et al.
Clinical Lymphoma Myeloma & Leukemia (2015)
Bortezomib-Based Versus Nonbortezomib-Based Induction Treatment Before Autologous Stem-Cell Transplantation in Patients With Previously Untreated Multiple Myeloma: A Meta-Analysis of Phase III Randomized, Controlled Trials
Pieter Sonneveld et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Improved survival of multiple myeloma patients with late relapse after high-dose treatment and stem cell support, a population-based study of 348 patients in Denmark in 1994-2004*
Annette J. Vangsted et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2010)
Effect of pamidronate 30 mg versus 90 mg on physical function in patients with newly diagnosed multiple myeloma (Nordic Myeloma Study Group): a double-blind, randomised controlled trial
Peter Gimsing et al.
LANCET ONCOLOGY (2010)
Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma
Jesus F. San Miguel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Share Paper
